A structure-based mechanism of cisplatin resistance mediated by glutathione transference P1-1

Anastasia De Lucaa,1, Lorien J. Parkerb,c,1, Wee Han Angd, Carlo Rodolfoa, Valentina Gabbarinib, Nancy C. Hancockb, Francesca Palonea,e, Anna P. Mazzettia, Laure Meninf, Craig J. Mortona,b,c, Michael W. Parkerb,c,2,3, Mario Lo Belloa,2, and Paul J. Dysonf,2,3

*Department of Biology, University of Rome Tor Vergata, 00133 Rome, Italy; bAustralian Cancer Research Foundation Rational Drug Discovery Centre, St. Vincent’s Institute of Medical Research, Fitzroy, VIC 3065, Australia; cDepartment of Biochemistry and Molecular Biology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Parkville, VIC 3010, Australia; dDepartment of Chemistry, National University of Singapore, 117506 Singapore; ePediatric Gastroenterology and Liver Unit, Department of Pediatrics, Sapienza University of Rome, 00161 Rome, Italy; and fInstitut des Sciences et Ingénierie Chimiques, École Polytechnique Fédérale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland

Edited by Robert Huber, Max Planck Institute of Biochemistry, Planegg-Martinsried, Germany, and approved May 23, 2019 (received for review February 28, 2019)

Cisplatin [cis-diaminedichloroplatinum(II) (cis-DDP)] is one of the most successful anticancer agents employed today and is effective against a wide range of solid tumors (1–3), including neuroblastoma (4), the extracranial neoplasm most commonly diagnosed in childhood (5). It has long been established that the mechanism of cis-DDP involves DNA intrastrand cross-link formation (6, 7), altering the molecular conformation of the double helix leading to apoptosis. In this context, the many DNA-binding proteins involved in these cellular processes play a fundamental role in the mechanism of cis-DDP and have been the subject of intense study (8), but the mode of tumor targeting and other molecular interactions have taken much longer to elucidate. Of note, only 5 to 10% of intracellular Pt is associated with the DNA fraction since, after cis-DDP enters the cell, there is a rapid formation of mono- and diaquo species in which 1 or 2 chloride ions are substituted by water molecules (9). These new species constitute the basis for the design and synthesis of new GST inhibitors able to circumvent cisplatin resistance.

cisplatin | drug resistance | glutathione transference | protein crystallography | protein–ligand interactions

Significance

The resurgence of platinum-based chemotherapy in the last few years has renewed interest in the field, including clinical studies of cisplatin in combination with resistance modulators. Indeed, cisplatin is one of the most successful anticancer agents, effective against a wide range of solid tumors. However, its use is restricted by side effects and/or by intrinsic or acquired drug resistance. We propose here a new mechanism of cisplatin resistance mediated by glutathione transference (GST) P1-1, as a cisplatin-binding protein. Our results show that cisplatin can be inactivated by this protein with the aid of 2 solvent-accessible and reactive cysteines. These findings may constitute the basis for the design and synthesis of new GST inhibitors able to circumvent cisplatin resistance.


The authors declare no conflict of interest.

This article is a PNAS Direct Submission.

This open access article is distributed under Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND).

Data deposition: The models reported in this paper have been deposited in the Research Collaboratory for Structural Bioinformatics Protein Data Bank, https://www.rcsb.org/ [PDB ID nos. SDUM (cis-DPP complex) and SDIJ (cis-DPP–GSH complex)].

1A.D.L. and L.J.P. contributed equally to this work.
2M.W.P., M.L.B., and P.J.D. contributed equally to this work.
3To whom correspondence may be addressed. Email: mparker@svi.edu.au or paul.dyson@epfl.ch.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1903297116/-/DCSupplemental.

Published online June 20, 2019.
Table 1. Enzymatic activity of GST P1-1 in cells overexpressing GST P1-1 WT and C47S, C101S, and C47S/C101S mutant enzymes

<table>
<thead>
<tr>
<th>Samples</th>
<th>Specific activity, U/mg</th>
<th>Fold increase vs. SH-SYSY</th>
</tr>
</thead>
<tbody>
<tr>
<td>SH-SYSY</td>
<td>0.195 ± 0.09</td>
<td>—</td>
</tr>
<tr>
<td>SH-SYSY pTarget GST P1-1</td>
<td>1.865 ± 0.29</td>
<td>9.6</td>
</tr>
<tr>
<td>SH-SYSY pTarget GST P1-1 C47S</td>
<td>0.476 ± 0.04</td>
<td>2.4</td>
</tr>
<tr>
<td>SH-SYSY pTarget GST P1-1 C101S</td>
<td>0.990 ± 0.07</td>
<td>5.1</td>
</tr>
<tr>
<td>SH-SYSY pTarget GST P1-1 C47S/C101S</td>
<td>0.430 ± 0.06</td>
<td>2.2</td>
</tr>
</tbody>
</table>

The enzymatic activity was determined as reported in the Materials and Methods section. The fold increases in the enzymatic activity of the transfected vs. untransfected cells are reported. Values are expressed as means ± SD from 3 independent experiments.
**Time Course Inactivation of GST P1-1 with cis-DDP.** cis-DDP was shown to inhibit GST P1-1 activity under certain conditions. When GST P1-1 (10 μM) was incubated without GSH in the presence of 1 mM cis-DDP, time-dependent inactivation of the enzyme was observed, which was faster in 10 mM potassium phosphate buffer with 2 mM NaCl than in PBS (pH 7.4) (Fig. 2D). After 15 min, the residual activity of GST P1-1 was about 25% of the initial activity. The addition of DTT (DL-dithiothreitol) did not recover the enzymatic activity. In contrast, in the presence of 10 mM GSH in PBS, WT GST P1-1 appeared resistant to cis-DDP deactivation (Fig. 2D). Inactivation of GST P1-1 occurred more rapidly at low concentrations of NaCl, with the order—in both rate and extent of inactivation—being WT > C47S > C101S. The C101S mutant retained 60% residual activity after 40 min of incubation, whereas the WT was completely inactivated over the same time period (Fig. 2D).

**cis-DDP Treatment Promotes the Cross-Linking of Both GST P1-1 Subunits, in the Absence of GSH, by Platination of C47 and C101.** To assess the platination of GST P1-1 by cis-DDP, WT GST P1-1 and its mutants, C47S and C101S, were each incubated in a 1:1 protein-to-drug ratio (50 μM) at 37°C for up to 72 h. Subsequent analysis by SDS/PAGE (sodium dodecyl sulphate/polyacrylamide gel electrophoresis) under nonreducing conditions showed that the Pt-free WT and C47S samples migrated, for the most part, as a single species with an approximate molecular mass of 24 kDa. ESI-MS analysis confirmed the molecular mass as 23,216 Da in WT GST P1-1 (Fig. 3A, peak A) and 23,199 Da in the C47S mutant (Fig. 3B, peak A), corresponding to the anticipated masses of the enzymes calculated from their amino acid sequences. The peaks at 23,346 in the WT (Fig. 3A, peak B) and at 23,330 in the C47S mutant (Fig. 3B, peak B) may be attributed to the incomplete removal of the N-terminal methionine residue (labeled with asterisks in Table 2) (34). In contrast, the apo form of the C101S mutant produced 2 bands, at ~24 and 20 kDa (Fig. 3C, Inset). ESI-MS analysis identified a single species with a molecular mass of 23,330 Da (Fig. 3C, peaks A and B), suggesting the bands observed by gel electrophoresis are due to different conformers of the protein.

Incubation of WT GST P1-1 with cis-DDP resulted in complete cross-linking of the dimer during the first 24 h (Fig. 3A, Inset), with 2 bands, migrating at ~49.5 and 46 kDa, appearing in the gel. With time, the lower molecular band was noticeably more intense. Multiple higher-molecular-weight bands were observed after 8 h, possibly due to the formation of oligomers of the enzyme. ESI-MS confirmed the molecular mass of the dimer species as 46,433 Da for WT GST P1-1 (Fig. 3A, peak C). ESI-MS analysis after 8 h of incubation identified equivalent peaks in both the C47S and C101S mutant samples (Fig. 3B and C, peak C). After 8 h of incubation with cis-DDP, the WT spectra showed an additional 3 peaks (Fig. 3A, peaks E, F, and G) corresponding to the dimeric form of the WT enzyme with 2 (peaks E and F) or 3 (peak G) Pt species (Table 2). The C47S mutant spectra suggest the formation

---

**Fig. 1.** GST P1-1 protects tumor cells against toxicity and apoptosis following cis-DDP treatment. (A) Cell viability of SH-SY5Y cell lines expressing WT and mutated GST P1-1, after cis-DDP administration. MTS assay was performed on cells treated with 5 μM cis-DDP for 24 h. Values, normalized to untreated control cells, are expressed as means ± SD from 3 independent experiments. Statistical significance compared with untreated samples (Student’s t test); *P < 0.05, **P < 0.01, ***P < 0.001. SH-SY5Y, nontransfected cells; –, cis-DDP–negative samples; +, after exposure to cis-DDP 5 μM for 24 h. (B) FACS analysis of apoptosis induction of SH-SY5Y cell lines expressing WT and mutated GST P1-1, after cis-DDP administration for 24 h. Values are expressed as means ± SD from 6 independent experiments; *P < 0.05. (C) Cytofluorometric analysis of apoptosis induction of SH-SY5Y cell lines expressing WT and mutated GST P1-1, after cis-DDP administration for 6 h followed by a recovery for additional 24 h. Values are expressed as means ± SD from 6 independent experiments; *P < 0.05.
of multiple covalent adducts containing 2 Pt species with or without chloride ligands (Fig. 3B, peaks, D, E, and F). In contrast, the C101S mutant appeared to have a single dimeric species (Fig. 3C, peak L), but multiple monomeric adducts attributed to C101S with 1 or 2 Pt species (Fig. 3C, peaks F, G, H, and I; see also Table 2). The data of the C101S mutant are also consistent with the gel electrophoresis experiments in which a band was observed around 50 kDa before the addition of cis-DDP that intensified with time, but did not represent the majority of the protein. Rather, a laddering effect of higher-molecular-weight species accounts for the majority of the protein species at 72 h. The rate of intersubunit cross-linking of all of the WT, C47S, and C101S proteins was accelerated as the concentration of cis-DDP increased (SI Appendix, Fig. S2).

Structure of GST P1-1–cis-DDP Complex in the Absence of GSH. The crystal structure of WT GST P1-1 complexed to cis-DDP was determined to a resolution of 1.9 Å. Cis-DDP was found to bind to the dimer interface of WT GST P1-1 in 2 different modes. In the major binding mode, cis-DDP is bound to C101 of each subunit, causing 2 of its ligands to be displaced (Fig. 4). Alternatively, cis-DDP binds to the protein via just one C101 ligand, termed the minor binding mode. The occupancy for the Pt in the major mode refines to 0.7, while that in the minor mode refines to 0.6. In the major binding mode, the cysteine residues bind to the Pt ion in a trans arrangement, suggesting one chloride/aquo and one amine ligand have been displaced. Binding of protein thiol to cis-DDP can exert a strong trans influence that is known to lead to the displacement of Pt-bound amine ligands (35). The density maps showed no evidence of ligands other than the cysteines, possibly because they are obscured due to the strong scattering of the electron-dense Pt ion, although more ligands are required to complete the expected square planar coordination geometry of the Pt(II) ion. The Pt–sulfur bond lengths for the major cis-DDP binding mode are around 2.3 Å, which are within the range 2.26 to 2.80 Å, similar to values observed in crystal structures of other Pt–sulfur complexes (36, 37).

Superposition of the WT GST P1-1–cis-DDP complex onto the GSH complex structure (PDB ID no. 5GSS) (38) shows that the protein structures are essentially identical with an rms deviation of 1.9 Å. There are no significant movements of side chains in the active site or at the dimer interface, with one exception. The region around helix α2 exhibited poor electron density in the cis-DDP complex, consistent with the helix being highly mobile. Similar observations have been made previously for other GST P1-1 crystal structures with empty G sites (39). In subunit A, electron density for residues 36 to 45 is absent, whereas in subunit B, electron density for residues 35 to 37 and 39 to 46 is absent, although that for residues 47 to 51 is visible but of poor quality. Of particular note is the extensive water network that is normally observed at the dimer interface, including a ring of 5 water molecules that surround C101, which is severely disrupted by Pt binding.

Structure of GST P1-1–cis-DDP Complex in the Presence of GSH. The crystal structure of WT GST P1-1 bound to GSH and complexed to cis-DDP was determined to a resolution of 1.8 Å. The structure revealed 3 Pt atoms bound at the dimer interface in the major and minor binding modes described above, albeit at significantly lower occupancies than in the GSH-free structure (the level of cis-DDP for protein binding is presumably significantly reduced in the presence of free GSH). The satellite Pt refine to...
an occupancy of 0.2, and the major Pt to 0.3. In this structure, the side chains of C101 could be built in 2 alternative conformations, with the Pt–sulfur distances consistent, with one conformation binding Pt (the same conformation observed in the GSH-free structure), and the other conformation being one that is adopted when no Pt is bound. A GSH molecule was found bound at the G site of each subunit, as observed previously for other GSH complexes, but there was no evidence of a Pt ion bound to the GSH. The occupancy of bound GSH was refined to 0.65. Comparison with the GSH-free complex described above shows that the protein structures are essentially identical for 389 residues, with an rms deviation of 0.3 Å. In this structure, however, several of the dimer-interface water molecules observed in the apo structure, but not in the GSH-free structure described above, are present. In the GSH-bound structure, helix α2 is well ordered.

**Discussion**

The use of the highly successful anticancer drug *cis*-DDP is limited by innate and acquired drug resistance. Although this process is multifactorial, GST P1-1 has been implicated in the resistance mechanism, and elevated GST P1-1 expression can occur in response to drug treatment but commonly occurs as part of the cancer phenotype irrespective of drug exposure. Given that, it is widely accepted that most cancer drugs are not good substrates for GST P1-1, and the role of this enzyme in drug resistance may be unrelated to GSH conjugation but involves, instead, one of the other functions of GST P1-1 (40). GST P1-1, unlike other GST proteins, has solvent-accessible cysteine residues that act as regulatory sensors. Specifically, posttranslational modifications of C47 are thought to modify the function of the protein, with *S*-glutathionylation leading to oligomerization and

---

**Fig. 3.** *cis*-DDP acts as an effective alkylating agent of GST P1-1, in the absence of GSH, by cross-linking both subunits. (A–C) Deconvoluted ESI-MS spectra of 50 μM GST P1-1 (A), C47S (B), and C101S (C) after 8 h of incubation at 37 °C in the absence or presence of 50 μM *cis*-DDP. Peaks are labeled with letters, and the corresponding molecular masses are reported in Table 2. (A–C, Insets) The time course analysis by SDS/PAGE, under nonreducing conditions of the incubation mixture for up to 72 h.
carboxymethylation (41) or S-nitrosylation (42) reducing affinity for GSH through changes in the preequilibrium between the open and closed conformations of helix α2. Moreover, previous site-directed mutagenesis experiments have suggested that C47 is one of several key residues that cause structural perturbations of helix α2 that are, in turn, transmitted through Y49 to the neighboring subunit (43). Therefore, C47 is thought to be involved both in regulation of the transferase function of the protein and in intersubunit communication. C101 has also been implicated in regulation of activity, with reports of similar posttranslational

### Table 2. Observed mass peaks of GST P1-1 and its mutant forms incubated with cis-DDP

<table>
<thead>
<tr>
<th>Enzyme</th>
<th>Peak</th>
<th>Molecular mass, Da</th>
<th>Assignment</th>
<th>Relative abundance, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>GST P1-1</td>
<td>A</td>
<td>23,216</td>
<td>GST P1-1 monomer</td>
<td>50</td>
</tr>
<tr>
<td></td>
<td>B</td>
<td>23,347</td>
<td>GST P1-1* monomer</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td>C</td>
<td>46,433</td>
<td>GST P1-1 dimer</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>D</td>
<td>23,216</td>
<td>GST P1-1 monomer</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td>E</td>
<td>46,860</td>
<td>GST P1-1 dimer + 2x[Pt(NH3)]</td>
<td>74</td>
</tr>
<tr>
<td></td>
<td>F</td>
<td>47,093</td>
<td>GST P1-1 dimer + 2x[Pt(NH3)] + [Pt(NH3)2]</td>
<td>82</td>
</tr>
<tr>
<td></td>
<td>G</td>
<td>47,429</td>
<td>GST P1-1* dimer + 3x[Pt(NH3)Cl]</td>
<td>91</td>
</tr>
<tr>
<td>C47S</td>
<td>A</td>
<td>23,199</td>
<td>C47S monomer</td>
<td>98</td>
</tr>
<tr>
<td></td>
<td>B</td>
<td>23,330</td>
<td>C47S* monomer</td>
<td>89</td>
</tr>
<tr>
<td></td>
<td>C</td>
<td>46,398</td>
<td>C47S dimer</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>D</td>
<td>23,753</td>
<td>C47S* monomer + 2x[Pt(NH3)]</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td>E</td>
<td>46,824</td>
<td>C47S dimer + 2x[Pt(NH3)]</td>
<td>54</td>
</tr>
<tr>
<td></td>
<td>F</td>
<td>47,164</td>
<td>C47S dimer + 2x[PtCl2] + [Pt(NH3)2]</td>
<td>24</td>
</tr>
<tr>
<td>C101S</td>
<td>A</td>
<td>23,199</td>
<td>C101S monomer</td>
<td>36</td>
</tr>
<tr>
<td></td>
<td>B</td>
<td>23,330</td>
<td>C101S* monomer</td>
<td>97</td>
</tr>
<tr>
<td></td>
<td>C</td>
<td>46,398</td>
<td>C101S dimer</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>D</td>
<td>23,199</td>
<td>C101S monomer</td>
<td>30</td>
</tr>
<tr>
<td></td>
<td>E</td>
<td>23,235.5</td>
<td>C101S monomer + MeOH</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td>F</td>
<td>23,524</td>
<td>C101S* monomer + Pt</td>
<td>26</td>
</tr>
<tr>
<td></td>
<td>G</td>
<td>23,541</td>
<td>C101S* monomer + [Pt(NH3)]</td>
<td>16</td>
</tr>
<tr>
<td></td>
<td>H</td>
<td>23,734</td>
<td>C101S monomer + 2x[PtCl2]</td>
<td>28</td>
</tr>
<tr>
<td></td>
<td>I</td>
<td>23,752</td>
<td>C101S* monomer + 2x[Pt(NH3)]</td>
<td>74</td>
</tr>
<tr>
<td></td>
<td>L</td>
<td>46,464.5</td>
<td>C101S dimer + 2xMeOH</td>
<td>18</td>
</tr>
</tbody>
</table>

The relative abundance (%) of each peak is obtained after normalization to the tallest peak present in each spectra.

*Enzymes characterized by the presence of the N-terminal methionine residue.

[Fig. 4. cis-DDP can be sequestered by GST P1-1, in the presence of GSH, by binding at the dimer interface of the enzyme. (A) Final (2Fo − Fc) electron density map (contour level 1σ in blue) and anomalous difference Fourier maps (contour at 4σ in pink) focused on the dimer interface. The Pt ions are designated by the purple spheres. (B) Surface representation showing the Pt-binding site in relation to the active sites. The purple spheres are the Pt ions, and GSH is shown in stick fashion with carbon bonds in yellow, nitrogen atoms in dark blue, oxygen atoms in red, and sulfur atoms in gold.]
modifications to those of C47, but to a lesser extent. In addition, C47–C47 intersubunit and C47–C101 intrasubunit disulfide binding can occur, which inactivates the protein for GSH transferase activity (21).

To investigate the role of C47 and C101 in the direct interaction of GST P1-1 with cis-DDP, plasmids coding for the WT and cysteine mutant enzymes were transfected into neuroblastoma SH-SY5Y cells. These cells were treated with cis-DDP and then tested for cell viability and death. Cell viability studies show that GST P1-1 overexpression confers significant protection against cis-DDP and reduces apoptosis induced by the drug at any dose administered, confirming the role of GST P1-1 in cis-DDP resistance. Of note, single point mutations of the cysteine residues affording the C47S or C101S variants reduce this protection, giving an order of cis-DDP sensitivity, determined by the proliferation assay and FACS analysis, as C101S > C47S > WT GST P1-1. Therefore, C101 appears to be more important because mutation of this residue makes cells more sensitive to cis-DDP compared with mutation of C47. C101 is more solvent accessible than C47, although, surprisingly, it has been relatively overlooked in previous studies compared with C47. Platination of C101 cannot sterically hinder GSH binding based on its location in the crystal structures. Therefore, the observation that the C101 mutant has a greater effect on cis-DDP resistance compared with mutation of C47 suggests that the mechanism may not involve GSH conjugation. Furthermore, the rate of in vitro formation of the cis-DDP adduct with GSH only slightly changes in the presence of the enzyme. Thus, the proposition that the role of GST P1-1 in cis-DDP inactivation is due to enzymatic conjugation of GSH with cis-DDP is not supported (14, 44, 45), but the GST P1-1–induced resistance to cis-DDP–induced cell death is instead mediated by one of its other functions (40). Note that it has also been suggested that the isoenzyme alpha (hGST A1-1) is also involved in cis-DDP resistance, but the biochemical mechanism underlying GST A1-1–mediated cis-DDP resistance has not been clarified (46).

The crystal structure of WT GST P1-1 in the presence of cis-DDP shows Pt binding in 1 of 2 different modes at the dimer interface of the protein, both involving C101 as ligands, further confirming the role of C101 in cis-DDP binding. GST P1-1 appears to sequester the Pt species, offering protection against cytotoxicity and cell death. The major binding mode shows cis-DDP mediating an intersubunit cross-link via the C101 residues, whereas the minor binding mode shows cis-DDP bound to a single C101 and possibly represents an intermediate stage before intersubunit cross-linking is complete. Pt sequestration does not cause substantial changes in the conformation of the protein, but notably, there is an increase in mobility of helix α2, which is most likely due to the absence of GSH from the G site and also perhaps due to Pt binding to C47. It is worth noting that the interaction of GST P1-1 with cis-DDP inactivates the enzyme, in the absence of GSH, in a time-dependent manner. The order of inactivation follows the order WT–Pt > C47S–Pt > C101S–Pt, which is inversely related to the order of cis-DDP sensitivity as measured by the proliferation assay. In contrast, incubation of GST P1-1 with cis-DDP in the presence of GSH preserves the transferase function. However, the crystal structure clearly shows Pt and GSH binding to different sites, and thus the preserved transferase function is not due to GSH sterically inhibiting Pt binding, indicating that in the intracellular GSH environment GST P1-1 is able to both sequester Pt and conjugate GSH to hydrophobic substrates such as CDNB (1-cloro-2,4-dinitrobenzene).

MS and gel electrophoresis studies further confirmed the role of the C101 residue in cis-DDP intersubunit cross-linking. Indeed, incubation of GST P1-1 and C47S with cis-DDP resulted in significant enzyme dimerization, apparent from the relative abundance calculated for each species of the enzyme (Table 2). In contrast, in the C101S mutant, dimerization is hardly observed, strongly confirming that Pt-induced cross-linking requires the C101 residue. Based on these data, we can also suggest that the enzyme accommodates up to 3 Pt ions per dimer, presumably at the various cysteine positions. These observations are further confirmed by the altered cytotoxicity of cis-DDP after treating SH-SY5Y cells transfected with the WT enzyme and its cysteine mutants. In particular, in the absence of C101, cis-DDP is not sequestered by the enzyme and its cytotoxicity is almost comparable to that exerted on nontransfected cells (Fig. 1B). The removal of both cysteines (C101S/C47S mutant) eliminates all possible cis-DDP anchor points on the enzyme, allowing it to exert its cytotoxic action unperturbed (Fig. 1B). Moreover, a Pt concentration dependence is observed in the formation of multiple Pt interactions, with a higher ratio of Pt accelerating the rate of cross-linking and progression toward a single species (SI Appendix, Fig. S2).

![Cartoon representation of the proposed mechanism of GST P1-1–mediated resistance to cis-DDP.](image-url)
The data show that cis-DDP is not a substrate for the GSH transferase activity of GST P1-1. Rather, the Pt species is sequestered and inactivated at the dimer interface where interactions with C101 are transmitted to the active site via helix α2. Thus, GST P1-1 is able to induce cis-DDP resistance in cancer cells through its function as a ligandin, while leaving its enzymatic activity intact, and possibly affecting GST P1-1 signaling function. Indeed, GST P1-1 binding to JNK prevents JNK phosphorylation, which is required for downstream apoptosis signaling (31, 32, 47–49). When GST P1-1 is cross-linked, for example via disulfide bridges, due to UV (ultraviolet) irradiation or oxidative stress, JNK is re-leased and activated (47), signaling for apoptosis. It could be postulated that overexpression of GST P1-1, besides sequestering Pt via C101 binding and thus preventing Pt-mediated apoptosis, could also impair sufficient release of JNK to trigger the cell death.

Another important aspect in the process of acquisition of cis-DDP resistance in cancer cells concerns the intracellular content of GSH (Fig. 5). It has been shown that GSH tends to be elevated in breast, ovarian, head and neck, and lung cancer (50), and it is known, and further demonstrated here, that intracellular GSH can conjugate with cis-DDP spontaneously, significantly lowering its bioavailability. Together, our results suggest that elevated GST P1-1 expression plays an important cytoprotective role against cis-DDP through Pt sequestration, which could confer resistance to chemotherapy, due to the intracellular transporter function of GST P1-1 rather than via the GSH transferase activity previously reported. However, considering the multiple levels of action of GST P1-1, the importance of this mechanism relative to other cis-DDP detoxification/resistance mechanisms remains to be established. Moreover, the relative contribution of this mechanism is expected to be highly dependent on the type of cancer or cancer cell line.

Materials and Methods

Cell Cultures. Human neuroblastoma SH-SY5Y cells were purchased from the European Collection of Cell Cultures (Salisbury, United Kingdom) and grown in Dulbecco’s modified Eagle’s F12 medium supplemented with 10% (vol/vol) heat-inactivated fetal bovine serum, 100 U/mL penicillin, and 100 μg/mL streptomycin, in a humidified atmosphere with 5% (vol/vol) CO2 in air.

Cell Lysis and Protein Concentration Determination. Cells were lysed in 10 mM Tris-HCl (pH 7.4) containing 10 mM DTT and 10 mM phenylmethylsulfonyl fluoride, through 3 s–s cycles of sonication. After centrifugation for 20 min at 13,000 rpm at 4 °C, protein concentration was determined using the Bradford method (Bio-Rad).

GST P1-1 Enzymatic Activity. The enzymatic activity of WT or mutants was assayed spectrophotometrically, following the method described by Habig and Jakoby (51).

Western Blotting. Forty micrograms of total protein extracted from cell lysates was resolved on SDS/PAGE (12% gels) under nonreducing conditions and transferred on to a nitrocellulose membrane (Bio-Rad) as previously described (52). The origin of the signals related to GST P1-1 was evaluated by densitometric analysis, using actin as control.

Western Blotting. Forty micrograms of total protein extracted from cell lysates was resolved on SDS/PAGE (12% gels) under nonreducing conditions and transferred on to a nitrocellulose membrane (Bio-Rad) as previously described (52). The origin of the signals related to GST P1-1 was evaluated by densitometric analysis, using actin as control.

Time Course Inactivation of GST P1-1 and Its Cysteine Mutants in the Presence of cis-DDP. WT GST P1-1 and its cysteine mutants (0.2 mg/mL, 10 μM in active sites) were incubated in 1 mL (final volume) of PBS or in 10 mM phosphate buffer solution plus 2 mM NaCl (pH 7.4) in the presence of 1 mM cis-DDP at 37 °C. At fixed times, over a period of 40 min, aliquots of sample (5 μL) were withdrawn from the mixture and assayed for residual GST activity in 100 mM phosphate buffer (pH 6.5) containing 1 mM GSH and 1 mM CDBN. As control, we incubated GST P1-1 alone or in the presence of 1 mM cis-DDP and 1 mM GSH, or in PBS.

ESI-MS Analysis of the GST P1-1–cis-DDP Interaction. WT GST P1-1 and the C47S and C101S mutants (50 μM) were each incubated with cis-DDP (50 μM) in potassium phosphate buffer solution (pH 7.0) at 37 °C for 8 h. The samples were withdrawn from the mixture and assayed for mass spectrometry by infusion at a flow rate of 20 μL/min with a solution of aceto-nitrile, H2O, and formic acid [55:44:9:0.1, vol/vol/vol]. A solution of phosphoric acid at 0.01% was used as an external celebrant. ESI-MS data were acquired on a Q-Tof Ultima mass spectrometer (Waters) employing a standard Z-spray ion source and operated in positive ionization mode. Instrument parameters were as follows: capillary voltage, 3.5 kV; source temperature, 80 °C; desolvation temperature, 120 °C; sample cone voltage, 50 V; desolvation gas flow, 400 L/h; acquisition window, 300 to 2,000 m/z in 1 s (53). Data processing was performed using the MassLynx 4.1 software.

X-Ray Crystallography. Crystallization was performed by the hanging drop vapor diffusion method as previously described (54). Crystals were grown in either the presence or absence of 10 mM GSH. Both crystal structures were solved by molecular replacement (SI Appendix, Table S1). The identification of Pt ions in the electron density maps was confirmed by anomalous scattering data.

Statistical Analysis. All experiments were performed at least 3 times. Statistical analysis was performed by Student’s t test using GraphPad Prism analysis software package (GraphPad Software, San Diego, CA). P < 0.05 was considered significant.

Protein Data Bank Accession Numbers. The models have been deposited in the Research Collaboratory for Structural Bioinformatics Protein Data Bank (https://www.rcsb.org/) under PDB ID nos. 5DJM (cis-DDP complex) and SDJL (cis-DDP–GSH complex).

Acknowledgments. We would like to thank Prof. Mario Lo Bello for having dedicated his entire scientific life to the study of glutathione transference. We thank the National Centre of Competence in Research in Chemical Biology (Switzerland) for financial support. We thank Drs. Jade Atiken, David Ascher, Mike Gorman, Guido Hansen, and Hugh Harris for advice and encouragement; and Harry Tong, other BioCARS staff, and Julian Aitken and their help with data collection at the Advanced Photon Source Synchrotron. This work, including use of the BioCARS sector, was supported by the Australian Synchrotron Research Program, which was funded by the Commonwealth of Australia under the Major National Research Facilities Program. Use of the Advanced Photon Source was supported by the US Department of Energy, Basic Energy Sciences, Office of Energy Research. This work was also supported by grants from the Australian Research Council and the Australian Cancer Research Foundation (to M.W.P.), and from the Minister of Instruction, University and Research and Genesys SpA (to M.L.B.). Funding from the Victorian Government Operational Infrastructure Support Scheme to St. Vincent’s Institute is acknowledged. L.J.P. was supported by a National Health and Medical Research Council of Australia (NHMRC) Dora Lush Scholarship and an International Centre for Diffraction Data Crystallography Scholarship. M.W.P. is an NHMRC Research Fellow.


L. Prade, R. Huber, B. Bieseler, Structures of herbicides in complex with their de-enzyme in plants. Xenobiotica 46, 25–33 (2016).


D. Rolland, M. Raharijaona, A. Barbarat, R. Houlgatte, C. Thieblemont, Inhibition of GSTP1 nuclear transfer increases mantle cell lymphoma sensitivity to cisplatin, cytarabine, gemcitabine, bortezomib and doxorubicin. In Cancer Res. 70, 3591–3597 (2010).


M. Zou et al., Glutathione S-transferase isozyme alpha 1 is predominantly involved in the cisplatin resistance of common types of solid cancer. Oncol. Rep. 41, 989–998 (2019).


T. Asakura et al., Conformational change in the active center region of GST P1-1, due to binding of a synthetic conjugate of DKR with GSH, enhanced JNK-mediated apoptosis. Apoptosis 12, 1269–1280 (2007).


